Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544984 | 0.81 | KIF11 (0.47) | SCN2ANPY5RNPC1PDCD1CD274 | |
| SCHEMBL7497622 | 0.78 | CYP17A1 (0.42) | KMONOTUMIDO1 | |
| SCHEMBL7210508 | 0.75 | IDO1 (0.53) | SCN2AKMONOTUMIDO1NPY5R | |
| SCHEMBL5056973 | 0.75 | ACHE (0.42) | KMONOTUMNPY5RNPC1RAB9A | |
| SCHEMBL16719513 | 0.75 | HSD17B1 (0.47) | — | |
| SCHEMBL1968839 | 0.75 | NOTUM (0.42) | SCN2AKMOKCNA5NOTUMIDO1 | |
| SCHEMBL16458195 | 0.74 | GRM2 (0.37) | ALDH1A1NPC1RAB9A | |
| SCHEMBL7972131 | 0.74 | SCN2A (0.44) | SCN2AKMONOTUMIDO1ALDH1A1 | |
| SCHEMBL1202054 | 0.73 | NOTUM (0.37) | NOTUMALDH1A1NPY5RNPC1RAB9A | |
| SCHEMBL29678302 | 0.72 | TSHR (0.58) | SCN2ANOTUMIDO1ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | claimed |
| CN-106536507-B | 2, 3-disubstituted pyridine compounds as TGF- β inhibitors and methods of use thereof | 里格尔药品股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| EP-2334683-B1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | MSD ITALIA SRL (IT) | 2017-03-22 | — | — | EP | disclosed |
| CN-106536507-A | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | 里格尔药品股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | disclosed |
| US-8470823-B2 | Saturated bicyclic heterocyclic derivatives as SMO antagonists | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-06-25 | — | — | US | disclosed |
| US-20110183989-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | Instituto di Ricerche di Biologia Molecolare P. Ang | 2011-07-28 | — | — | US | disclosed |
| EP-2334683-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010023480-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-03-04 | — | — | WO | disclosed |
| US-4833143-A | PHENYL CYCLOBUTYL HETEROCYCLIC AMINES AND AMIDES | THE BOOTS COMPANY PLC (GB) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183989-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | SMO, SHH, GLI1 | SCN2A 3355/4885KMO 1239/4885KCNA5 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.